BNT211-01: A phase I trial to evaluate safety and efficacy of CLDN6 CAR T cells and CLDN6-encoding mRNA vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumours
ANNALS OF ONCOLOGY (2022)
期刊
ANNALS OF ONCOLOGY
卷 33, 期 7, 页码 S1404-S1405出版社
ELSEVIER
关键词
类别
资金
- BioNTech Cell & Gene Therapies GmbH
作者
我是这篇论文的作者
推荐
CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial
Andreas Mackensen, John B. A. G. Haanen, Christian Koenecke, Winfried Alsdorf, Eva Wagner-Drouet, Peter Borchmann, Daniel Heudobler, Barbara Ferstl, Sebastian Klobuch, Carsten Bokemeyer, Alexander Desuki, Florian Lueke, Nadine Kutsch, Fabian Mueller, Eveline Smit, Peter Hillemanns, Panagiotis Karagiannis, Erol Wiegert, Ying He, Thang Ho, Qing Kang-Fortner, Anna Melissa Schlitter, Catrine Schulz-Eying, Andrew Finlayson, Carina Flemmig, Klaus Kuehlcke, Liane Preussner, Benjamin Rengstl, Oezlem Tuereci, Ugur Sahin
NATURE MEDICINE (2023)
Comparison of two lab-scale protocols for enhanced mRNA-based CAR-T cell generation and functionality
Nadine von Auw, Robert Serfling, Reni Kitte, Nadja Hilger, Chengkang Zhang, Clara Gebhardt, Anna Duenkel, Paul Franz, Ulrike Koehl, Stephan Fricke, U. Sandy Tretbar
SCIENTIFIC REPORTS (2023)
Universal redirection of CAR T cells against solid tumours via membrane-inserted ligands for the CAR
Angela Q. Zhang, Alexander Hostetler, Laura E. Chen, Vainavi Mukkamala, Wuhbet Abraham, Lucia T. Padilla, Alexandra N. Wolff, Laura Maiorino, Coralie M. Backlund, Aereas Aung, Mariane Melo, Na Li, Shengwei Wu, Darrell J. Irvine
NATURE BIOMEDICAL ENGINEERING (2023)
A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus
Allison August, Husain Z. Attarwala, Sunny Himansu, Shiva Kalidindi, Sophia Lu, Rolando Pajon, Shu Han, Jean-Michel Lecerf, Joanne E. Tomassini, Marjie Hard, Leon M. Ptaszek, James E. Crowe, Tal Zaks
NATURE MEDICINE (2021)
Characterization of BNT162b2 mRNA to Evaluate Risk of Off- Target Antigen Translation
Himakshi K. Patel, Kun Zhang, Rachael Utegg, Elaine Stephens, Shauna Salem, Heidi Welch, Svenja Grobe, Julia Schlereth, Andreas N. Kuhn, Jeff Ryczek, David J. Cirelli, Thomas F. Lerch
JOURNAL OF PHARMACEUTICAL SCIENCES (2023)
mRNA vaccine encoding Gn provides protection against severe fever with thrombocytopenia syndrome virus in mice
Jae-Yong Kim, Kyeongseok Jeon, Sang-In Park, Yoo-Jin Bang, Hyeong-Jun Park, Hye Won Kwak, Do-Hyung Kim, Soo-Yeon Lee, Eun-Jin Choi, Nam-Hyuk Cho, Jae-Hwan Nam
NPJ VACCINES (2023)
Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment
Alessio Amatu, Arianna Pani, Giorgio Patelli, Oscar M. Gagliardi, Marina Loparco, Daniele Piscazzi, Andrea Cassingena, Federica Tosi, Silvia Ghezzi, Daniela Campisi, Renata Grifantini, Sergio Abrignani, Salvatore Siena, Francesco Scaglione, Andrea Sartore-Bianchi
EUROPEAN JOURNAL OF CANCER (2022)
Construction and Immunogenicity of Modified mRNA-Vaccine Variants Encoding Influenza Virus Antigens
Ekaterina V. Starostina, Sergei V. Sharabrin, Denis N. Antropov, Grigory A. Stepanov, Georgiy Yu. Shevelev, Anna E. Lemza, Andrey P. Rudometov, Mariya B. Borgoyakova, Nadezhda B. Rudometova, Vasiliy Yu. Marchenko, Natalia V. Danilchenko, Anton N. Chikaev, Sergei I. Bazhan, Alexander A. Ilyichev, Larisa I. Karpenko
VACCINES (2021)
CLIC-01: Manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies
Natasha Kekre, Kevin A. Hay, John R. Webb, Ranjeeta Mallick, Miruna Balasundaram, Mhairi K. Sigrist, Anne-Marie Clement, Julie S. Nielsen, Jennifer Quizi, Eric Yung, Scott D. Brown, Lisa Dreolini, Daniel D. Waller, Julian Smazynski, Nicole S. Gierc, Bianca C. Loveless, Kayla Clark, Tyler Dyer, Richard Hogg, Leah McCormick, Michael Gignac, Shanti Bell, D. Maria Chapman, David Bond, Siao Yong, Rachel Fung, Heather M. Lockyer, Victoria Hodgson, Catherine Murphy, Ana Subramanian, Evelyn Wiebe, Piriya Yoganathan, Liana Medynski, Dominique C. Vaillan, Alice Black, Sheryl McDiarmid, Michael Kennah, Linda Hamelin, Kevin Song, Sujaatha Narayanan, Judith A. Rodrigo, Stefany Dupont, Terry Hawrysh, Justin Presseau, Kednapa Thavorn, Manoj M. Lalu, Dean A. Fergusson, John C. Bell, Harold Atkins, Brad H. Nelson, Robert A. Holt
FRONTIERS IN IMMUNOLOGY (2022)
LRP2 and DOCK8 Are Potential Antigens for mRNA Vaccine Development in Immunologically 'Cold' KIRC Tumours
Shichao Zhang, Kaide Xia, Yue Chang, Yimei Wei, Yu Xiong, Fuzhou Tang, Jian Peng, Yan Ouyang
VACCINES (2023)
Positive aspects of the mRNA platform for SARS-CoV-2 vaccines
Khalid Hajissa, Ali Mussa
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2021)
Exploring in vitro expression and immune potency in mice using mRNA encoding the Plasmodium falciparum malaria antigen, CelTOS
Ishita N. N. Waghela, Katherine L. L. Mallory, Justin A. A. Taylor, Cosette G. G. Schneider, Tatyana Savransky, Chris J. J. Janse, Paulo J. C. Lin, Ying K. K. Tam, Drew Weissman, Evelina Angov
FRONTIERS IN IMMUNOLOGY (2022)
Severe treatment-refractory antibody positive autoimmune autonomic ganglionopathy after mRNA COVID19 vaccination
Simon Rowe, Judith M. Spies, Nicolas Urriola
AUTOIMMUNITY REVIEWS (2022)
Protective Immune Responses Induced by an mRNA-LNP Vaccine Encoding prM-E Proteins against Japanese Encephalitis Virus Infection
Tao Chen, Shuo Zhu, Ning Wei, Zikai Zhao, Junjun Niu, Youhui Si, Shengbo Cao, Jing Ye
VIRUSES-BASEL (2022)
An mRNA vaccine encoding Chikungunya virus E2-E1 protein elicits robust neutralizing antibody responses and CTL immune responses
Ningning Ge, Jin Sun, Zhihua Liu, Jiayi Shu, Huimin Yan, Zhihua Kou, Yu Wei, Xia Jin
VIROLOGICA SINICA (2022)
ASO Visual Abstract: Is a History of Optimal Staging by SLNB in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?
Stephanie A. Blankenstein, Johannes J. Bonenkamp, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Christian U. Blank, Willeke A. M. Blokx, Marye J. Boers-Sonderen, Alfons J. M. van den Eertwegh, Margreet G. Franken, Jan Willem B. de Groot, John B. A. G. Haanen, Geke A. P. Hospers, Ellen W. Kapiteijn, Olivier J. van Not, Djura Piersma, Rozemarijn S. van Rijn, Karijn P. M. Suijkerbuijk, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Hans M. Westgeest, Michel W. J. M. Wouters, Alexander C. J. van Akkooi
ANNALS OF SURGICAL ONCOLOGY (2023)
Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?
Stephanie A. Blankenstein, Johannes J. Bonenkamp, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Christian U. Blank, Willeke A. M. Blokx, Marye J. Boers-Sonderen, Alfons J. M. van den Eertwegh, Margreet G. Franken, Jan Willem B. de Groot, John B. A. G. Haanen, Geke A. P. Hospers, Ellen W. Kapiteijn, Olivier J. van Not, Djura Piersma, Rozemarijn S. van Rijn, Karijn P. M. Suijkerbuijk, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Hans M. Westgeest, Michel W. J. M. Wouters, Alexander C. J. van Akkooi
ANNALS OF SURGICAL ONCOLOGY (2023)
Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study
Monique K. van der Kooij, Arjen Joosse, Karijn P. M. Suijkerbuijk, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Christian U. Blank, Marye J. Boers-Sonderen, Alfonsus J. M. van den Eertwegh, Jan Willem B. de Groot, John B. A. G. Haanen, Geke A. P. Hospers, Djura Piersma, Rozemarijn S. van Rijn, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Hans M. Westgeest, Michel W. J. M. Wouters, Olaf M. Dekkers, Ellen Kapiteijn
BRITISH JOURNAL OF CANCER (2023)
Novel strategies to improve efficacy of treatment with tumor-infiltrating lymphocytes (TILs) for patients with solid cancers
Liselotte Tas, Inge Jedema, John B. A. G. Haanen
CURRENT OPINION IN ONCOLOGY (2023)
γδ T cells are effectors of immunotherapy in cancers with HLA class I defects
Natasja L. de Vries, Joris van de Haar, Vivien Veninga, Myriam Chalabi, Marieke E. Ijsselsteijn, Manon van der Ploeg, Jitske van den Bulk, Dina Ruano, Jose G. van den Berg, John B. Haanen, Laurien J. Zeverijn, Birgit S. Geurts, Gijs F. de Wit, Thomas W. Battaglia, Hans Gelderblom, Henk M. W. Verheul, Ton N. Schumacher, Lodewyk F. A. Wessels, Frits Koning, Noel F. C. C. de Miranda, Emile E. Voest
NATURE (2023)
Identification of patient-specific CD4+ and CD8+ T cell neoantigens through HLA-unbiased genetic screens
Chiara M. M. Cattaneo, Thomas Battaglia, Jos Urbanus, Ziva Moravec, Rhianne Voogd, Rosa de Groot, Koen J. J. Hartemink, John B. A. G. Haanen, Emile E. E. Voest, Ton N. N. Schumacher, Wouter Scheper
NATURE BIOTECHNOLOGY (2023)
Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis
Melissa M. M. De Meza, Willeke A. M. Blokx, Johannes J. J. Bonenkamp, Christian U. U. Blank, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Marye J. J. Boers-Sonderen, Jan Willem B. De Groot, John B. A. G. Haanen, Geke A. P. Hospers, Ellen Kapiteijn, Olivier J. J. Van Not, Djura Piersma, Rozemarijn S. S. Van Rijn, Marion Stevense-den Boer, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Alfonsus J. M. van den Eertwegh, Karijn P. M. Suijkerbuijk, Michel W. J. M. Wouters
CANCERS (2023)
Exposure-response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients
Stefanie L. Groenland, J. M. Janssen, C. M. Nijenhuis, N. de Vries, H. Rosing, S. Wilgenhof, J. V. van Thienen, J. B. A. G. Haanen, C. U. Blank, J. H. Beijnen, A. D. R. Huitema, N. Steeghs
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2023)
Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma
Isabella A. J. van Duin, Sjoerd G. Elias, Alfonsus J. M. van den Eertwegh, Jan Willem B. de Groot, Willeke A. M. Blokx, Paul J. van Diest, Tim Leiner, Joost J. C. Verhoeff, Rik J. Verheijden, Olivier J. van Not, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Christian U. Blank, John B. A. G. Haanen, Geke A. P. Hospers, Anna M. Kamphuis, Djura Piersma, Rozemarijn S. van Rijn, Astrid A. M. van Der Veldt, Gerard Vreugdenhil, Michel W. J. M. Wouters, Marion A. M. Stevense-den Boer, Marye J. Boers-Sonderen, Ellen Kapiteijn, Karijn P. M. Suijkerbuijk
INTERNATIONAL JOURNAL OF CANCER (2023)
Adjuvant treatment of in-transit melanoma: Narrowing the knowledge gap left by clinical trials
Melissa M. de Meza, Willeke A. M. Blokx, Han J. Bonenkamp, Cristian U. Blank, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Marye J. Boers-Sonderen, Jan Willem B. de Groot, John B. Haanen, Geke A. P. Hospers, Ellen W. Kapiteijn, Olivier J. van Not, Djura Piersma, Rozemarijn S. van Rijn, Marion A. Stevense-Den A. Boer, Astrid A. M. van Der Veldt, Gerard Vreugdenhil, Alfons J. M. van den Eertwegh, Karijn P. M. Suijkerbuijk, Michel W. J. M. Wouters
INTERNATIONAL JOURNAL OF CANCER (2023)
Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands
Michiel C. T. van Zeijl, Jesper van Breeschoten, Liesbeth C. de Wreede, Michel W. J. M. Wouters, Doranne L. Hilarius, Christian U. Blank, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Jan Willem B. de Groot, Geke A. P. Hospers, Ellen Kapiteijn, Djura Piersma, Rozemarijn S. van Rijn, Marion Stevense-den A. Boer, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Marye J. Boers-Sonderen, Karijn P. M. Suijkerbuijk, John B. A. G. Haanen, Alfons J. M. van den Eertwegh
JOURNAL OF IMMUNOTHERAPY (2023)
Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma
J. B. A. G. Haanen, J. Larkin, T. K. Choueiri, L. Albiges, B. I. Rini, M. B. Atkins, M. Schmidinger, K. Penkov, E. Michelon, J. Wang, M. Mariani, A. di Pietro, R. J. Motzer
ESMO OPEN (2023)
OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum
Tetje C. van der Sluis, Guillaume Beyrend, Esme T. I. van der Gracht, Tamim Abdelaal, Simon P. Jochems, Robert A. Belderbos, Thomas H. Wesselink, Suzanne van Duikeren, Floortje J. van Haften, Anke Redeker, Laura F. Ouboter, Elham Beyranvand Nejad, Marcel Camps, Kees L. M. C. Franken, Margot M. Linssen, Peter Hohenstein, Noel F. C. C. de Miranda, Hailiang Mei, Adriaan D. Bins, John B. A. G. Haanen, Joachim G. Aerts, Ferry Ossendorp, Ramon Arens
CELL REPORTS MEDICINE (2023)
CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial
Andreas Mackensen, John B. A. G. Haanen, Christian Koenecke, Winfried Alsdorf, Eva Wagner-Drouet, Peter Borchmann, Daniel Heudobler, Barbara Ferstl, Sebastian Klobuch, Carsten Bokemeyer, Alexander Desuki, Florian Lueke, Nadine Kutsch, Fabian Mueller, Eveline Smit, Peter Hillemanns, Panagiotis Karagiannis, Erol Wiegert, Ying He, Thang Ho, Qing Kang-Fortner, Anna Melissa Schlitter, Catrine Schulz-Eying, Andrew Finlayson, Carina Flemmig, Klaus Kuehlcke, Liane Preussner, Benjamin Rengstl, Oezlem Tuereci, Ugur Sahin
NATURE MEDICINE (2023)
ZENYTH-ESO: Master protocol to assess the safety and recommended phase II dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma, myxoid/round cell liposarcoma and non-small cell lung cancer [Substudy 1 (GSK3901961) and Substudy 2 (GSK3845097)]
Roland Ullrich, Martin Wermke, Jeffrey Yachnin, Stephan Mielke, Reema Patel, Melinda L. Yushak, Adam J. Schoenfeld, Jayesh Desai, Mehmet Altan, Sandra P. D'angelo, Jonathan Noujaim, John B. A. G. Haanen, Benjamin Powers, Thomas Faitg, Wenlei Liu, Nitin Patel, Dejka M. Araujo
ONCOLOGY RESEARCH AND TREATMENT (2022)